Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7435247 | 0.85 | KDM4E (0.57) | ARKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL6516194 | 0.84 | ALDH1A1 (0.46) | ARKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL27930539 | 0.81 | KDM4E (0.41) | ARKDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL858817 | 0.81 | AR (0.57) | ARKDM4EALDH1A1HSD17B10PARP1 | |
| SCHEMBL858842 | 0.81 | TAS1R3 (0.55) | ARPARP1 | |
| SCHEMBL29503134 | 0.81 | AR (0.54) | ARKDM4EALDH1A1HSD17B10PARP1 | |
| SCHEMBL7360846 | 0.80 | KDM4E (0.64) | KDM4EALDH1A1HSD17B10LMNAMAPT | |
| SCHEMBL24960102 | 0.79 | AR (0.60) | ARPARP1 | |
| SCHEMBL29503125 | 0.79 | AR (0.53) | ARPARP1 | |
| SCHEMBL30219271 | 0.77 | AR (0.50) | ARMAPTTDP1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | TRIACT THERAPEUTICS, INC. | 2020-09-24 | — | — | US | disclosed |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | BIPAR SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | BIPAR SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | BIPAR SCIENCES, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | BIPAR SCIENCES, INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | BIPAR SCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | BIPAR SCIENCES | 2009-05-21 | — | — | US | disclosed |
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | BIPAR SCIENCES | 2009-05-21 | — | — | US | disclosed |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES | 2009-05-14 | — | — | US | disclosed |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | BIPAR SCIENCES | 2009-05-14 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008030891-A2 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030883-A2 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131529-A1 | Poly/ADP-Ribose/polymerase inhibitors (PARP); administering 4-iodo-3-nitrobenzamide, gemcitabine, and carboplatin; gene therapy | PARP2, PARP1, PARP3 | AR 105/4885KDM4E 3053/4885ALDH1A1 612/4885 |
| US-20200297644-A1 | INIPARIB FORMULATIONS AND USES THEREOF | INPP5B, INPPL1, PARP3 | AR 56/4885KDM4E 3120/4885ALDH1A1 1362/4885 |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | PARP2, PARP12, PARP3 | AR 693/4885KDM4E 1356/4885ALDH1A1 349/4885 |
| US-20090123419-A1 | TREATMENT OF UTERINE CANCER AND OVARIAN CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTI-TUMOR AGENTS | PARP2, PARP1, PARP3 | AR 1190/4885KDM4E 564/4885ALDH1A1 543/4885 |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | PARP2, PARP12, PARP15 | AR 1551/4885KDM4E 1002/4885ALDH1A1 484/4885 |
| US-20120269861-A1 | TREATMENT OF BREAST CANCER WITH IODONITROBENZAMIDES IN COMBINATION WITH ANTI-TUMOR AGENTS | ERBB2, EGFR, ERBB3 | AR 62/4885KDM4E 2001/4885ALDH1A1 932/4885 |
| US-20120245117-A1 | METHODS OF TREATING SQUAMOUS CELL LUNG CANCER WITH 4-IODO-3-NITROBENZAMIDE IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN | IDH3B, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1 | AR 3497/4885KDM4E 3405/4885ALDH1A1 154/4885 |
| US-20080103104-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | AR 964/4885KDM4E 1377/4885ALDH1A1 794/4885 |
| US-20130274281-A1 | METHODS OF TREATING METASTATIC BREAST CANCER WITH 4-IODO-3-NITROBENZAMIDE AND IRINOTECAN | TOP2B, TOP2A, TOP1 | AR 4080/4885KDM4E 3666/4885ALDH1A1 1190/4885 |
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | AR 964/4885KDM4E 1377/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.